Teva holding off launch of opioid addiction drug
Drugmaker awaiting outcome of separate court case
Drugmaker awaiting outcome of separate court case
Pfizer and Eli Lilly are competitors in NGF research
Regulator cites issues with manufacturing plant
Troubled generics giant Teva is continuing the heavy pruning of its business and has cut a novel migraine drug from its pipeline.
Aimovig notches up another late-stage trial success